Alpha Tau Medical Ltd. - Warrant (OQ:DRTSW)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

May 21, 2024 08:45 am ET

Alpha Tau to Present at the Jefferies Global Healthcare Conference

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the...

May 20, 2024 04:01 pm ET

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2024 financial results and provided a corporate update. "This...

May 13, 2024 08:30 am ET

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been treated in a...

May 06, 2024 08:30 am ET

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of the European...

May 01, 2024 08:30 am ET

Alpha Tau to Participate in May Investor Conferences

Mar 25, 2024 08:50 am ET

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 07, 2024 04:01 pm ET

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2023 financial results and provided a corporate update. “2023 was an...

Feb 26, 2024 08:30 am ET

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate at the Barclays 26th Annual Global Healthcare...

Dec 20, 2023 09:15 am ET

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Chairman and CEO Uzi Sofer and CFO Raphi Levy will present a corporate...

Nov 29, 2023 08:30 am ET

Alpha Tau to Participate in Sidoti Small-Cap Conference

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will present at the Sidoti Small-Cap Virtual Conference on...

Nov 28, 2023 08:30 am ET

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in...

Nov 20, 2023 08:30 am ET

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercialization platform...

Nov 16, 2023 04:30 pm ET

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update. "This year...

Nov 01, 2023 08:30 am ET

Alpha Tau to Participate in November Investor Conferences

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences in...

Oct 30, 2023 08:30 am ET

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its U.S. subsidiary, Alpha Tau Medical Inc., has entered into a long-term...

Oct 24, 2023 09:00 am ET

Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug...

Sep 14, 2023 08:30 am ET

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that a patient with advanced inoperable pancreatic cancer has been treated in...

Aug 28, 2023 04:02 pm ET

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2023 financial results and provided a corporate update. “This year we...

Aug 24, 2023 08:00 am ET

Alpha Tau Medical to Participate in September Investor Conferences

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences....

Aug 17, 2023 05:00 pm ET

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today initial long-term safety and tumor control outcomes for patients with...

Aug 02, 2023 09:00 am ET

Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present at the Emerging Growth...

May 24, 2023 04:01 pm ET

Alpha Tau Medical to Participate in June Investor Conferences

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences....

May 23, 2023 04:01 pm ET

Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2023 financial results and provided a corporate update. "This year we...

May 17, 2023 04:30 pm ET

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

May 11, 2023 04:00 pm ET

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the publication of the results of its US multicenter pilot trial in JAMA...

May 03, 2023 04:00 pm ET

Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part in a fireside chat at...

Apr 03, 2023 09:10 am ET

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

Mar 29, 2023 04:00 pm ET

Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present in-person at the...

Mar 12, 2023 08:30 am ET

Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today issued the following statement on Silicon Valley Bank (SVB) in response to questions...

Mar 09, 2023 04:10 pm ET

Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2022 financial results and provided a corporate update. "We are proud of...

Mar 08, 2023 05:00 pm ET

Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that the first two patients were enrolled and treated today in its pivotal...

Mar 03, 2023 08:30 am ET

Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli Ministry of Environmental Protection has granted the Company...

Mar 01, 2023 08:30 am ET

Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has received authorization from Health Canada to proceed with a...

Feb 21, 2023 04:00 pm ET

Alpha Tau to Participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Company plans to participate in Citi’s 2023 Healthcare Services,...

Dec 13, 2022 08:00 am ET

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

Nov 22, 2022 04:02 pm ET

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2022 financial results and provided a corporate update. "Alpha...

Nov 09, 2022 08:00 am ET

Alpha Tau to Present at Upcoming November Investor Conferences

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Company will present in person at the following investor conferences in...

Oct 21, 2022 04:01 pm ET

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today its participation in the upcoming 2022 Annual Meeting of the American Society...

Sep 08, 2022 04:05 pm ET

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demon

Alpha Tau Medical Ltd. ("Alpha Tau") (Nasdaq: DRTS and DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the acceptance of two landmark pre-clinical studies in major peer-reviewed journals, both...

Sep 01, 2022 04:15 pm ET

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company’s Board of...

Aug 30, 2022 04:05 pm ET

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Company will participate in person at three upcoming investor conferences in September 2022....

Aug 25, 2022 04:05 pm ET

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2022 financial results and provided a corporate update. "We have...

Mar 28, 2022 08:00 am ET

Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update

JERUSALEM, March 28, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2021 financial results and provided a corporate update.

Ad blocking detected

Alpha Tau Medical Ltd. - Warrant (OQ:DRTSW)

Business Focus: N/A